MassChallenge

HeroSupport is a medical device manufacturing company founded in 2019 and based in Veyrier, Geneva. The company specializes in creating medical immobilization devices designed to enhance patient comfort during clinical procedures. Its innovative technology transforms imaging and treatment tables into personalized support solutions, specifically catering to the needs of patients undergoing prone breast radiotherapy. This approach allows patients to benefit from tailored support, eliminating the need for them to adjust to the standard table. By improving patient comfort, HeroSupport enables healthcare providers to deliver more effective and cost-efficient cancer treatment.

Embryoxite is a biotechnology company specializing in non-invasive diagnostic services for pre-implantation embryos in human-assisted reproduction. It operates a platform that combines artificial intelligence, metabolomics, embryo imaging, and clinical data to enhance embryo selection accuracy and improve patient outcomes for fertility clinics and reproductive specialists.

Pharmesol is a clinical services company that develops a platform to automate follow-up care for medications. The platform uses artificial intelligence to automate calls and messages, streamlining communication among patients, providers, and payers, and supports data management with recorded documentation. This enables patients and doctors to receive personalized support around the clock.

Corveus Medical is a medical device company focused on innovative solutions for preventing heart failure. The company is developing a neuromodulation device designed to perform nerve ablation through a catheter-based approach. This minimally invasive technology aims to effectively target and access specific tissues, offering a novel treatment option for heart failure. By addressing both the clinical and economic challenges associated with this condition, Corveus Medical seeks to improve patient outcomes and enhance the overall management of heart failure.

Dart Biosciences works in the healthcare industry. It creates tailored gene therapies for a variety of uncommon and prevalent disorders.

CranioSense develops non-invasive medical devices to diagnose and monitor intracranial hypertension, providing clinicians with crucial insights for treating neurological conditions.

Speratum is a biopharmaceutical company focused on microRNA-directed oncology therapies. The Company was founded in 2014 by Christian Marín-Müller, Ph.D. and is dedicated to the development of a patented treatment for pancreatic cancer based on the combination of tumor suppressive microRNA molecules and nanoparticle-based drug delivery technologies. The Company is currently entering the final stage of preclinical trials for the pancreatic cancer therapy, while simultaneously expanding the patent’s coverage to incorporate other types of cancer and non-cancer indications and illnesses and expanding its intellectual property (IP) portfolio with complementary technologies in the fields of nanotechnology, medical devices and veterinary medicine.

electronRx specializes in digital medicine solutions for chronic disease management. They develop personalized healthcare platforms that monitor cardiovascular health remotely, enabling patients to self-manage their conditions with clinical oversight.

Cellorama multipurpose devices, reagents, and processes are patent-pending and protect cell structure and integrity during many procedures. User-friendly and cost-effective devices are designed to minimize stressful stages in the laboratory while saving time and vital resources.

ZiO Health is a biotechnology company that develops pocket-sized devices featuring proprietary biosensor technology and machine learning algorithms. These devices enable real-time laboratory testing at the point-of-care, enhancing patient care by combining immediate results with individual patient profiles.

Narval is a biotechnology company specializing in the development of synthetic antibody mimetic proteins (AMPs). These AMPs are significantly smaller than conventional antibodies, yet retain their biological functionality. They offer several advantages, including the ability to penetrate tissue barriers, generate limited immune reactions, target small and hard-to-reach antigens, and withstand heat. This technology enables Narval to create novel first-in-class immunotherapeutics for diseases previously challenging to treat using monoclonal antibodies. Their focus includes respiratory, eye, and autoimmune diseases, with delivery methods such as inhaled antibodies, eye drops, and transdermal patches. Narval leverages machine learning and artificial intelligence to optimize its drug development capabilities.

Flagler Health develops clinical decision support software that helps healthcare providers deliver more comprehensive care. Its platform uses patient data and clinical guidelines to identify potentially beneficial procedures that might have been overlooked, improving patient outcomes.

Stellate Therapeutics is a global biotechnology company specializing in the development of small molecules derived from human gut bacteria into personalized therapies for neurological diseases. The company's platform has generated a portfolio of new drug candidates, with capabilities spanning discovery, screening, production, and diagnostic development.

Trove Health is a company that offers a clinical trial recruitment platform designed to facilitate access to patient data for patients, healthcare providers, and life sciences organizations. The platform creates a diverse and consented database of prospective trial participants, enabling researchers to efficiently identify and recruit patients who meet specific enrollment criteria across various geographies and therapeutic areas. By doing so, Trove Health supports the advancement of medical research while empowering patients to manage their own health data, including the potential to monetize it and receive personalized treatment options.

Developer of cancer drugs designed to help treat solid tumors. The company focuses on treating cancer diseases using biomaterials, enabling healthcare professionals to improve survival rates, reduce adverse effects, and offer new hope to patients.

Women aged 20-45 cannot get screened for breast cancer because existing solutions are unreliable. However, 81% want to. At The Blue Box, we have built a pain-free, low-cost, sensitive, radiation-free device to detect breast cancer in urine with a sensitivity of 83%. In 2024, we’ll launch into the market, bringing The Blue Box to private gynecology clinics with a Diagnostics-as-a-Service subscription model, and a pay-per-test revenue stream that we’ll share with doctors.

Arnav Biotech is a biotechnology company that operates as a Contract Development and Manufacturing Organization (CDMO), specializing in mRNA technology. It offers services for the design, development, and manufacturing of custom and cataloged mRNA products, supporting research, therapeutics, and vaccines. By providing these services, Arnav Biotech enables researchers to concentrate on their specific areas of interest, thereby democratizing access to mRNA-based life sciences.

SafeGuard Surgical is a medical device company focused on improving surgical outcomes and patient safety. It develops innovative, resorbable products designed to enhance colonic anastomotic healing and stability during advanced surgical procedures. These include a resorbable intraluminal stent graft and an extraluminal resorbable graft, along with anvil cap extension arms. By employing these products, SafeGuard aims to reduce surgical complications, lower healthcare costs, and minimize patient recovery time, ultimately preventing mortality and morbidity associated with surgery.

Lura Health develops a non-invasive continuous health monitoring platform that uses saliva as a diagnostic fluid. The company integrates micro-sensors into orthodontic devices such as retainers, aligners, and brackets to continuously measure saliva analytes and securely transmit data to a smartphone app, enabling users to monitor oral health metrics and potentially support broader chronic disease management. Target markets include heart disease, chronic kidney disease, diabetes, and tooth decay. Founded in 2017, the company is based in Cambridge, Massachusetts.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Eupnoos is a health-tech company specializing in digital lung health solutions. It offers smartphone-based, automated lung function testing and data interpretation for various devices and telehealth platforms.

Delfina is a data-driven prenatal care platform that personalizes pregnancy care to improve safety for mothers and babies. It uses a data-powered approach to uncover insights in prenatal care and to optimize interventional workflows through machine learning models. The platform creates individualized pregnancy care plans based on patient risk assessed from multiple metrics and supports early intervention, helping providers deliver equitable, cost-effective care. By integrating data across clinical, demographic, and monitoring inputs, Delfina aims to enhance decision-making, streamline workflows, and improve outcomes throughout pregnancy.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Opsin Biotherapeutics specializes in the development of gene therapies based on opsins, a class of light-sensitive proteins. The company's primary focus is to create a pipeline of treatments for pain management, aiming to provide effective alternatives to opioids.

Selmod, based in Basel's life science hub, develops innovative antibiotics targeting multi-drug resistant infections. Its first-in-class drug candidates focus on high-revenue hospital patients where first-line treatments have failed due to resistance. With a disruptive approach featuring new dual modes of action, all candidates have shown success in animal infection studies. The company aims to capture a significant share of the estimated $9 billion total available market for its three lead assets.

Ronawk is a biotechnology company specializing in the development of T-Block technology that produces patient-specific biologics for the treatment of various diseases, including cancer, organ injuries, and burns. The company's proprietary method allows for the growth of primary stem cells in a three-dimensional environment, preserving the essential characteristics of these cells outside the human body. This innovative approach enables the rapid expansion of stem cells, facilitating their use in early-stage diagnostics and the repair of damaged tissues. Ronawk's technology not only enhances the efficiency of growing human cells but also supports tissue generation and disease modeling, making significant contributions to the fields of regenerative medicine and reconstructive surgery.

Netnoids Rx Laboratories operates a cancer contract research organization that uses patient-derived organoid model systems to help find a cure for rare cancers.

Condor empowers pharmaceutical and biotechnology companies to optimize financial resources during clinical development. Its software combines real-time data with automation and industry expertise to streamline workflows, enhance decision-making, and accelerate innovation.

Nightingale Caring Solutions enhances hospital operations by offering nursing care analytics. It employs machine learning algorithms to analyze relationships between nurses and patient outcomes, optimizing nurse staffing, scheduling, and assignments.

Delfina is a data-driven prenatal care platform that personalizes pregnancy care to improve safety for mothers and babies. It uses a data-powered approach to uncover insights in prenatal care and to optimize interventional workflows through machine learning models. The platform creates individualized pregnancy care plans based on patient risk assessed from multiple metrics and supports early intervention, helping providers deliver equitable, cost-effective care. By integrating data across clinical, demographic, and monitoring inputs, Delfina aims to enhance decision-making, streamline workflows, and improve outcomes throughout pregnancy.

Fora Health helps patients and clinicians track health and take part in shared decision-making. The company's platform links a patient-facing smartphone app with a clinical team web interface, powering remote patient monitoring and shared decision making. Fora Health is scaled to the needs of clinical teams, configuring data collected from validated ePROs and cognitive assessments, to goal tracking, medication adherence, and side effect tracking.

BioEclosion is a biotechnology company specializing in the development of user-friendly, rapid diagnostic tools. Its core technology, Celifast, is a non-invasive method for detecting celiac disease, validated and patented. The company aims to expand this platform to other emerging diseases, using molecular biomarkers for swift identification. BioEclosion's device comprises a single-use cartridge tailored to each application and a portable, battery-operated reader, making it versatile for human and veterinary health, as well as food and environmental safety.

Criam is a Portuguese biotechnology company based in Braga that develops portable diagnostic technology for blood typing and infectious disease detection. Its stand-alone platform does not require electricity or laboratory infrastructure, enabling rapid testing at the point of care. A single reader can perform multiple tests using cartridges and computer vision algorithms to detect a broad range of diseases, including HIV, with real-time data to support clinical decisions. The system leverages lab-on-a-chip concepts and biomarker detection algorithms to deliver fast, user-friendly, and cost-effective diagnostics in diverse settings, including remote environments and emergency care.

Paragit Solutions specializes in developing innovative systems for remote patient monitoring and data-driven clinical management of movement disorders, particularly Parkinson's disease. Central to their offerings is the Paragit Sleeve, which employs a patented sEMG (electromyography) technology to gather precise data on muscle activation, movement, and grip force during patients' daily activities. Paragit provides two main software suites for data interpretation: the PD Monitor, tailored for caregivers, which visualizes key motor symptoms like rigidity and tremors to enhance treatment optimization and facilitate telemedicine; and the MD Lab, designed for decentralized clinical trials across various movement disorders. MD Lab enables researchers to analyze over 20 metrics related to disease severity, track trends, and compare groups consistently, with a robust API that supports extensive data access for further analysis. Through these technologies, Paragit aims to improve the management and understanding of movement disorders, enhancing patient care and clinical research.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

Leucine Rich Bio is India's pioneering genomics-based company focused on microbiome analysis. It aims to bridge uncertainties in precision medicine by studying the 'second genome', offering personalized nutritional recommendations based on intestinal microflora, with applications across various health fields.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

Founded in Italy in 2016 by Silvia Scaglione and Maurizio Aiello, React4life is a biotech company dedicated to advancing biomedical research. The company specializes in the development of MIVO®, an innovative organ-on-a-chip technology that enhances the reliability and predictability of various applications such as pharmaceutical drug testing, personalized medicine, immuno-oncology therapies, cosmetics, dermatology, and nutraceuticals.

Matricelf is a biotechnology company focused on advancing tissue engineering and regenerative medicine. Founded in 2019 by Professor Tal Dvir from Tel Aviv University, the company specializes in the 3D printing of tissues and organs, utilizing a proprietary decellularization process that extracts stromal cells and extracellular matrix from small biopsy samples. This process generates a thermo-responsive hydrogel, which is then combined with reprogrammed induced pluripotent stem cells to create functional tissues through a patent-pending methodology. Matricelf is particularly dedicated to developing spinal cord implants for patients with traumatic injuries, aiming to restore neuronal activity and enhance motor functions, thereby improving patients' quality of life and facilitating their reintegration into the community.

UpLift Health Inc., based in Atlanta, Georgia, specializes in developing a digital application aimed at treating depression through cognitive behavioral therapy (CBT). Founded in 2018, the company offers a structured program that consists of twelve weekly sessions, each lasting approximately 40 minutes, designed to teach users effective coping skills. The application incorporates chatbot-guided interactions, allowing users to engage with mental exercises and receive feedback. Additionally, it provides daily tools for users to apply learned skills in their everyday lives. Preliminary research indicates that UpLift's program can significantly reduce symptoms of depression, with a reported reduction of 52% in pilot studies. The company is focused on its mission to assist one million individuals in overcoming depression.

Julota is an interoperability and community information platform that coordinates care across emergency responders, clinicians, caseworkers, and social services to improve public health and maximize the impact of limited local resources. The platform automates workflows, referrals, tracking, and communication among users, enabling healthcare, law enforcement, and social service organizations to collaborate and address community health and safety challenges.

Naviday Health develops a personalized, AI-guided care platform focused initially on menopause. It empowers users with tailored insights, symptom tracking, and holistic support, bridging the gap between traditional care and real-world health needs.

NUBIX stores and remotely interprets specialty studies connecting specialist with clinics, hospitals, laboratories and public and private cabinets, insurers and patients. We support the diagnosis by managing, storing and interpreting studies of specialty in 3 simple steps: storage of studies, access to studies from anywhere and interpretation of the study at any time. We improve the communication systems available between clinics and hospitals with medical specialists. Our focus is on 3 areas: insurers that seek to reduce their costs based on the reduction of mounted claims, clinics and public and private hospitals that do not have a radiologist or other specialist in their staff, to the public health sector as a third party authorized for distance interpretation and patients who are seeking a second medical opinion about their medical procedures. During its first year of operations (2018) NUBIX serves more than 39,000 patients including more than 35,000 patients for the early detection of breast cancer. Times of up to 25 hours for patient care are achieved through NUBIX compared to other options that take more than a month to perform the interpretation, this is very important since with most types of cancer Breast division takes one to two months, that is, the lesion doubles in size from a treatable finding to a high-risk one.

Sano Chemicals is an early‑stage biotechnology company that develops novel anti‑infectives for clinical and agricultural use. The company focuses on antifungal treatments for human infections such as nail, skin, and systemic diseases, and on bio‑control methods to protect crops from fungal pathogens. Its flagship compound, occidiofungin, was discovered by researchers at Mississippi State University and Texas A&M University and is being advanced for both medical and agricultural applications. In addition to antifungal work, Sano Chemicals explores therapies against antimicrobial‑resistant fungi and bacteria and investigates potential uses in oncology, aiming to improve patient outcomes and support a sustainable food supply.

Neurosoft Bioelectronics specializes in developing soft, implantable electrodes designed to interface with nervous tissues. Their flagship product, SOFT ECoG, is a subdural electrode used for recording and stimulating the brain's surface, offering improved recordings, reduced current speed, minimized MRI artifacts, enhanced bio-integration, and precise anatomical targeting.

Knot is a digital case log platform designed to support medical activities, particularly for surgical residency. It promotes learning and simplifies the reporting of surgical residency requirements by allowing residents to log cases via a mobile application.

Byteflies is a Belgian-American wearable health company dedicated to transforming healthcare through innovative technology. With its headquarters in Antwerp, Belgium, near key life sciences and clinical research centers, and a secondary office in the San Francisco Bay Area, the company is positioned at the intersection of healthcare and digital innovation. Byteflies develops advanced wearable health applications, including a sensor dot that captures biopotential signals, muscle activity, eye movement, and other activity-related data using an integrated inertial measurement unit. This technology empowers pharmaceutical companies, researchers, and tech firms to enhance healthcare delivery and improve patient outcomes. The team comprises experts in medicine, engineering, and data science, all committed to advancing health monitoring and management.

Adiposs is a clinical-stage life science company developing innovative medical imaging products. Its flagship technology enables the early detection of cachexia, a debilitating body-wasting syndrome associated with cancer and other chronic diseases.

OrganoTherapeutics is a company focused on developing medical drugs aimed at treating Parkinson's disease. It utilizes advanced human-specific mini-brain models that accurately replicate the pathology of Parkinson's disease for the discovery and development of effective drug candidates. By employing three-dimensional models derived from both healthy individuals and patients with Parkinson's disease, OrganoTherapeutics identifies the therapeutic potential of various compounds and analyzes data using artificial intelligence. This innovative approach facilitates the screening of new molecules, allowing researchers to advance novel drug candidates. The company has already developed proprietary drug candidates and has access to extensive libraries for further research and development.

Savvy Cooperative is a company that operates a platform focused on sharing health experiences within the healthcare industry. The platform enables patients to directly share their health journeys with innovators in the field, advocating for fair compensation for their contributions. By doing so, Savvy empowers patients to co-create new healthcare solutions, providing them with a sense of purpose and an opportunity to earn money. This approach helps healthcare industries gain valuable patient insights for clinical research, user experience design, and market analysis through various methods such as surveys, interviews, and focus groups.

Sana Health, Inc. is a digital health company based in Lafayette, Colorado, with an additional office in Mill Valley, California. Founded in 2015, the company specializes in developing bio-therapeutic devices designed to promote relaxation and alleviate pain and tension. Its flagship product, Sana, is a non-addictive mask and headphone combination that utilizes audiovisual stimulation to enhance the balance between the left and right sides of the brain, facilitating a deep meditative state. This device employs coordinated pulses of light and sound to guide users into relaxation, mimicking the benefits of long-term meditation practices. Sana Health is also engaged in multiple clinical studies, focusing on applications for conditions such as fibromyalgia and neuropathic pain, as well as trials related to anxiety and PTSD. The company offers its products for sale online and provides a mobile application accessible via major app platforms.

Onexio Biosystems is a research and development company. They offer HTS screens that typically utilize a single reporter cell type that lacks important confounding biology, including drug metabolism and paracrine and endocrine cell interactions. Their microDUO supports co-culture and multi-culture to improve human relevance in drug discovery and chemical screening.

Health Note is an AI-powered health data management platform that collects patient information through voice and digital intake tools, automatically formats it into clinical notes, and integrates with electronic medical records to streamline documentation and pre-visit workflows. The platform is frictionless and platform-agnostic, enabling patients to participate in their care without apps or portals and reducing administrative burden for clinicians while improving care team efficiency. Founded in 2018 and based in San Francisco, Health Note aims to simplify clinical documentation and EMR integration.

Tzofen is a biotechnology company focused on developing a novel biological platform aimed at treating various types of cancer. This innovative platform has demonstrated the ability to eliminate cancer growth both in vitro and in vivo, highlighting its potential to significantly impact cancer treatment. By advancing this technology, Tzofen seeks to contribute to saving millions of lives affected by cancer.

Clara Biotech is a biotechnology company that focuses on the isolation and purification of exosomes from small fluid samples, facilitating liquid biopsy applications for the early detection of diseases such as cancer and Alzheimer's Disease. The company's innovative platform overcomes traditional challenges in exosome harvesting, which typically relies on a lengthy ultra-centrifugation process. Clara Biotech's technology allows for the extraction of pure, viable exosomes from any biofluid source, enhancing the purity and potency of these cellular markers. In addition to advancing diagnostic capabilities, the platform also supports the development of precision medicine by enabling targeted drug delivery directly to specific cells. By bridging the gap between research and patient care, Clara Biotech positions itself at the forefront of exosome-related breakthroughs in the biopharmaceutical field.

Aniluxx Biotechnology, Inc. is a biopharmaceutical company focused on developing innovative topical therapeutics for companion animals affected by skin diseases. Founded in 2019 and based in Chapel Hill, North Carolina, the company aims to enhance the health and well-being of pets by creating treatments for conditions such as atopic dermatitis and osteoarthritis. Aniluxx Biotechnology’s approach leverages a pipeline of topically formulated therapeutics based on compounds that have demonstrated safety and efficacy in humans. These therapeutics are designed to be easy to apply and virtually unnoticeable, minimizing the harsh side effects often associated with systemic medicines. Through its commitment to improving animal care, Aniluxx Biotechnology seeks to provide pet owners with effective solutions for managing their pets' health issues.

Onena Medicines is a biotechnology company developing innovative biological medicines. It focuses on addressing large unmet clinical needs for breast cancer and other serious orphan illnesses.

InvivoSciences specializes in phenotypic compound screening services, focusing on first-in-class drug discovery and drug repositioning. The company's unique approach combines tissue engineering technology with assay automation and sample miniaturization to provide a rapid and cost-effective platform for therapeutic discovery.

Eupnoos is a health-tech company specializing in digital lung health solutions. It offers smartphone-based, automated lung function testing and data interpretation for various devices and telehealth platforms.

Sana Health, Inc. is a digital health company based in Lafayette, Colorado, with an additional office in Mill Valley, California. Founded in 2015, the company specializes in developing bio-therapeutic devices designed to promote relaxation and alleviate pain and tension. Its flagship product, Sana, is a non-addictive mask and headphone combination that utilizes audiovisual stimulation to enhance the balance between the left and right sides of the brain, facilitating a deep meditative state. This device employs coordinated pulses of light and sound to guide users into relaxation, mimicking the benefits of long-term meditation practices. Sana Health is also engaged in multiple clinical studies, focusing on applications for conditions such as fibromyalgia and neuropathic pain, as well as trials related to anxiety and PTSD. The company offers its products for sale online and provides a mobile application accessible via major app platforms.

Savvy Cooperative is a company that operates a platform focused on sharing health experiences within the healthcare industry. The platform enables patients to directly share their health journeys with innovators in the field, advocating for fair compensation for their contributions. By doing so, Savvy empowers patients to co-create new healthcare solutions, providing them with a sense of purpose and an opportunity to earn money. This approach helps healthcare industries gain valuable patient insights for clinical research, user experience design, and market analysis through various methods such as surveys, interviews, and focus groups.

Limbix is a company dedicated to developing prescription digital therapeutics for adolescent mental health. Their flagship product, SparkRx, is an evidence-based, clinically validated tool designed to treat depression and anxiety in teenagers. Limbix combines clinical expertise with technological innovation to deliver effective mental health treatments.

Byteflies is a Belgian-American wearable health company dedicated to transforming healthcare through innovative technology. With its headquarters in Antwerp, Belgium, near key life sciences and clinical research centers, and a secondary office in the San Francisco Bay Area, the company is positioned at the intersection of healthcare and digital innovation. Byteflies develops advanced wearable health applications, including a sensor dot that captures biopotential signals, muscle activity, eye movement, and other activity-related data using an integrated inertial measurement unit. This technology empowers pharmaceutical companies, researchers, and tech firms to enhance healthcare delivery and improve patient outcomes. The team comprises experts in medicine, engineering, and data science, all committed to advancing health monitoring and management.

Health Note is an AI-powered health data management platform that collects patient information through voice and digital intake tools, automatically formats it into clinical notes, and integrates with electronic medical records to streamline documentation and pre-visit workflows. The platform is frictionless and platform-agnostic, enabling patients to participate in their care without apps or portals and reducing administrative burden for clinicians while improving care team efficiency. Founded in 2018 and based in San Francisco, Health Note aims to simplify clinical documentation and EMR integration.

Embleema is a health data platform focused on improving the drug discovery process and accelerating the development of new treatments. The company empowers patients to take ownership of their medical data, facilitating direct connections with research studies and allowing patients to be compensated for sharing their information. By enhancing the collection and sharing of real-world evidence, Embleema aims to transform the traditional linear model of drug approval into a more efficient iterative process. This approach enables the healthcare system to generate regulatory-grade evidence, including genomic sequences and data on microbial pathogens, thereby reducing the time and costs associated with bringing life-saving drugs to market, particularly for patients with rare diseases.

Founded in 2018, Intus Care develops a platform that connects home care providers with patients. Its application uses machine learning to predict hospital readmissions and risks, enabling efficient tracking of care providers and high-risk patient identification.

CellSpring is a biotechnology company based in Zurich, Switzerland, that develops 3D tissue models for biological research. Its core offering, the 3D Bloom platform, enables rapid creation of biomimetic microtissues independent of cell type, supporting in vitro studies and drug development. The platform emphasizes speed, reliability, versatility, and ease of use, improving the fabrication of 3D cell cultures for diverse experimental applications.

Encapsulate is a biotechnology company focused on developing automated tumor-on-a-chip systems that facilitate personalized cancer treatment. The company's innovative technology allows for the growth of patients' cancer cells outside the body, creating micro tumors that can be preserved and utilized to assess the efficacy of various chemotherapy and biotherapeutic drugs. By screening the response profile of cancer patients to these treatments, Encapsulate aims to enable oncologists to tailor effective treatment regimens, improving outcomes in cancer care.

Founded in 2018, Intus Care develops a platform that connects home care providers with patients. Its application uses machine learning to predict hospital readmissions and risks, enabling efficient tracking of care providers and high-risk patient identification.

Butterfly Medical Ltd is a medical-device company founded in 2014 and based in Yokne'am, Israel. It specializes in the development of an implantable device aimed at treating Benign Prostatic Hyperplasia (BPH), a condition commonly referred to as enlarged prostate. The company's innovative device provides a fast, simple, and minimally invasive alternative to conventional BPH treatments, including medications and surgery. It can be implanted in under ten minutes in an office setting using local anesthesia, without the need for surgical incisions or removal of prostate tissue. This approach not only minimizes side effects but also eliminates the requirement for hospitalization or general anesthesia. Initial clinical trials have shown promising results, with effective outcomes in opening blocked urethras and no reported side effects. Butterfly Medical is advancing further clinical studies in leading medical centers across Europe to validate its device's efficacy and safety.

Regenosca SA is a Swiss company based in Lausanne, established in 2019, that specializes in the development and commercialization of innovative medical devices for bladder reconstruction. The company focuses on creating sterile, off-the-shelf implants that serve as viable alternatives to autologous tissue substitutes for soft tissue repair. By leveraging advanced biomaterials technology, Regenosca aims to facilitate regeneration rather than scarring, thereby enhancing patient outcomes and preserving bladder function. Their products are designed to be easy to use, ultimately improving the quality of life for patients undergoing bladder surgeries.

Terapet specializes in advanced proton therapy for cancer treatment. Founded by physicists Christina Vallgren, Marcus Palm, and Professor Raymond Miralbell from Geneva University Hospitals, the company offers precise radiotherapy that minimizes harm to healthy cells. Incorporated in 2019, Terapet is based in Geneva, Switzerland.

Combioxin is a clinical-stage biotechnology company focused on developing anti-virulence therapies to treat severe bacterial infections and address antibiotic resistance. Its approach centers on liposome-based constructs engineered to neutralize virulence factors produced by pathogens, with the aim of restoring health in critically ill patients, including those with severe bacterial pneumonia.

ATLASense Biomed develops ICU-grade wearable technology for continuous remote patient monitoring beyond ICU settings. Its chest-worn PolyMonitor provides non-invasive data and AI-driven analytics via the REPHAEL platform to enable early prediction of respiratory deterioration, heart failure, and sepsis signs. The system supports multiple clinical indications and can be used in hospital wards, post-acute care, and home environments, helping clinicians monitor patients in real time and trigger alerts. The company targets hospital-at-home applications, offering a single device for monitoring pulmonary and cardiovascular conditions such as COPD, ARDS, and COVID-19, with the goal of enabling preventive care and reducing the need for invasive interventions while improving patient management and outcomes.

Combinostics is a software company based in Tampere, Finland, that develops data-driven diagnostics tools to support clinical decision making in neurological disorders. It offers a cloud-based platform and imaging analysis solutions for brain MRI, PET and CT data, enabling quantitative assessment of brain images to assist in early diagnosis of neurodegenerative diseases and to improve treatment outcomes. The company provides software for image processing, biomarker analysis, and integration of patient data to give healthcare professionals a comprehensive view of patient information.

NeuroKaire develops personalized psychiatry testing tools. It uses innovative technology to predict the most effective drug treatment for patients, enabling faster recovery, fewer side effects, and lower dosing.

Founded in 2018, Resistell develops and markets a diagnostic device for phenotypic antibiotic susceptibility testing. Its unique method detects movement caused by living bacterial cells to determine bacterial resistance to antibiotics.

Oxalo Therapeutics develops therapies to treat rare kidney diseases and prevent recurrent oxalate-related stones, focusing on primary hyperoxaluria and other oxalate pathologies. It leverages microbiome science, translational research, and early-stage technology to create a gut-derived therapy that safely removes oxalate from the body, reducing stone recurrence and related renal complications.

EBT Medical, Inc. is a clinical-stage company based in Boston, Massachusetts, with an additional office in Toronto, Canada. Founded in 2014, the company specializes in developing innovative, non-invasive neuromodulation therapies aimed at treating pelvic health disorders, particularly focusing on patients with overactive bladder. EBT Medical's technology is centered on the Saphenous nerve and is designed to provide discreet treatment options that enable patients to restore pelvic health function without the side effects typically associated with conventional therapies. The company emerged from scientific discoveries made at the University of Toronto and has benefited from a startup incubation program that has fostered numerous successful ventures in the past decade.

Stithi Innovation is a healthcare company that focuses on enhancing medication compliance for patients on long-term medication regimens. It has developed a medical device that dispenses pills and monitors daily dosages over extended periods. By integrating real-time monitoring services and built-in cellular connections, Stithi's devices facilitate remote tracking of medication adherence by both healthcare providers and patients. This innovative approach aims to improve patient outcomes by ensuring that individuals adhere to their prescribed treatment plans.

Hippocrate operates a cloud-based healthcare analytics platform that stores and encrypts patients' medical records and enables secure sharing of EMR data among hospitals and authorized clinicians, accessible during doctor visits or emergencies and usable for medical research. Founded in 2014, the company is based in Tunis, Tunisia.

Founded in London in 2016, LIfT BioSciences develops a proprietary platform for allogeneic innate immuno-cell therapy. Its Neutrophil Only Leukocyte Infusion Therapy (N-LIfT®) enables scalable production of Immunomodulatory Alpha Neutrophils (IMAN®s) from induced pluripotent stem cells (iPSCs), offering potential mono or combo therapies.

ALAnostics is a specialty biopharmaceutical company that originated as a spin-off from the University of Geneva. It focuses on developing innovative tumor painting technology aimed at enhancing the surgical treatment of breast cancer. The company’s proprietary approach utilizes nanomedicines to create a fluorescent dye that targets early-stage tumors, facilitating real-time identification and removal during surgery. This technology, based on 5-ALA prodrugs, supports fluorescence-guided surgical procedures and incorporates light-activated antimicrobials, ultimately improving surgical outcomes and increasing the likelihood of saving patients' lives by ensuring complete tumor removal.

ImmunArtes is a biotechnology company focused on developing vaccines and therapeutics to combat Staphylococcus aureus (MRSA) infections. They aim to neutralize MRSA's immune evasion mechanisms, which contribute to increased antibiotic resistance.

Pilleve is a company focused on addressing the critical issue of opioid misuse and addiction, which has significantly impacted many Americans. By providing a remote monitoring system, Pilleve aims to reduce the risks associated with opioid prescriptions through real-time data collection and behavioral analysis. Their solution features an integrated pill bottle and a corresponding smartphone application that securely dispenses medication while monitoring patient intake. Patients must use biometric scanners or passwords to access their prescriptions, and they are prompted to report their pain levels and mood before dispensing medication. This process allows for the early detection of problematic behaviors, enabling healthcare providers to intervene promptly if patients exceed recommended dosages. By facilitating communication between patients and their physicians through electronic health records, Pilleve strives to improve patient safety and care, ultimately reducing the social and financial burdens tied to opioid addiction for patients and their families.

Kernal Biologics, Inc. is a biotechnology company focused on designing and developing mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company leverages its mRNA platform to enable researchers and organizations to create vaccines and therapeutics. Kernal’s innovative approach allows specific cells to produce their own therapeutic agents. With a team that has strong connections to prestigious institutions like MIT and Harvard, as well as experience in the pharmaceutical industry, Kernal Biologics has garnered recognition for its work, winning multiple awards from notable organizations, including Amgen and NASA.

ReviveMed develops a precision-medicine platform that transforms untargeted metabolomic data into actionable insights. Its network-based machine learning algorithm integrates metabolomics with other molecular information, facilitating the development of therapeutics for liver diseases.

Halo Life Science is a company dedicated to enhancing human health and wellness through innovative nutritional solutions. After three years of research and development, the company has introduced Naturalin™, a patent-pending phytonutrient designed to improve the nutritional value of everyday foods and beverages. This multifunctional bioactive is also available in various nutritional supplement formats, making it suitable for addressing chronic conditions, illnesses, and obesity. Supported by research from the Dell Pediatric Research Institute at The University of Texas at Austin, Naturalin™ has been validated for safety and efficacy. Halo Life Science's mission is to provide safe, effective, and accessible food and nutritional products to consumers, ensuring that enhanced nutrition is available to everyone, everywhere.

Healthimation is a healthcare company focused on addressing weight management issues, specifically for individuals with Type 2 Diabetes, Pre-Diabetes, and Obesity. Its flagship program, Why WAIT™, has over 12 years of proven effectiveness and combines structured meal plans, exercise regimens, and educational resources with engaging entertainment elements. This innovative approach ensures that users remain motivated and committed to their personalized health journeys. Healthimation's platform integrates evidence-based clinical programs with digital health technology, utilizing animation and interactive learning to enhance user engagement and improve health outcomes. By providing an affordable and scalable solution, Healthimation stands out in the market for its unique ability to deliver clinical care in a captivating manner that resonates with users and fosters better health management.

ThinkGenetic is an online platform that helps patients explore potential genetic causes of their medical issues and understand the impact of living with a genetic disease. The platform uses cognitive technology to identify possible genetic factors and guide users on what questions to ask clinicians, with the aim of speeding diagnosis and reducing diagnostic errors, thereby improving medical care for individuals with genetic conditions.

Day Zero Diagnostics develops sequencing-based diagnostics for infectious diseases. Its proprietary technologies enable rapid identification of bacterial species and antibiotic resistance profiles from clinical samples, targeting bloodstream infections and sepsis initially. The company aims to improve patient outcomes by providing comprehensive diagnoses within hours instead of days.

MobioSense is engaged in the development of advanced diagnostic solutions for heart disease. The company's flagship product, HERO, is a portable, high-sensitivity troponin test that enables rapid diagnosis of heart attacks. Unlike conventional tests that require multiple samples over an extended period, HERO can provide results in just three hours, facilitating immediate decision-making in both hospital and ambulance settings. This innovation not only improves patient care by allowing for timely interventions but also helps alleviate emergency room congestion by directing patients to the appropriate care pathways. In addition to its heart disease monitoring capabilities, MobioSense is also involved in creating detection reagents for diseases such as African Swine Fever and COVID-19, further enhancing its commitment to healthcare advancements.

Alleviant Medical, Inc. is a medical device company headquartered in Austin, Texas, that specializes in developing innovative therapies for congestive heart failure. Founded in 2017, the company has created a proprietary transcatheter device that addresses the symptoms of heart failure by relieving pressure buildup in the left atrium of the heart. This minimally-invasive technology aims to improve the quality of life for patients and significantly reduce hospital admissions related to heart failure exacerbations, ultimately benefiting millions of Americans affected by this condition. Alleviant Medical is committed to transforming the treatment landscape for congestive heart failure through its advanced medical devices.

MakerHealth is a global organization focused on democratizing health technology by enabling clinicians and frontline staff to design, prototype, and fabricate medical devices. Rooted in MIT's Little Devices Lab, it supports healthcare teams with prototyping kits, MakerHealth Spaces, and educational resources, empowering medical makers to develop practical tools and iterate in real-world settings. Through its community network, MakerHealth aims to expand access to health technology fabrication across hospitals worldwide and foster cultures of creative prototyping to improve patient care.

NerveSolutions is a biomedical technology company specializing in the development of implantable nerve interface devices. Its flagship product is a surgical device designed to prevent neuroma formation after amputation or nerve injury, enabling surgeons to provide optimal treatment and helping patients regain function.

Every day more than 1 million implants are placed into human and animal bodies using open surgery. Lumigbo has developed a technology to build up implants inside the body using an access channel of less than half a millimeter in diameter. The procedure can be used for almost any type of implant. We have developed minimally viable prototypes for neurovascular, orthopedic and dental applications. Currently, we are improving our prototypes and expect to close round A in the third quarter of 2018.

Structured Immunity is a protein engineering company focused on enhancing the safety and effectiveness of T cell receptor-based therapies. Founded in 2017 by David Hardwicke and Timothy Riley, the company leverages over 20 years of research from the laboratory of Brian Baker to develop advanced techniques for optimizing T cell receptors. By increasing the target specificity of these receptors, Structured Immunity aims to improve drug efficacy while minimizing potential side effects associated with T cell therapies. The company specializes in enhancing the human immune system for cell-based cancer immunotherapy, providing pharmaceutical firms with innovative solutions for engineering patentable cellular cancer therapies with improved tumor targeting capabilities.

SuraMedical is an early-stage company founded in 2016 that develops WoundAlert, a remote patient monitoring solution for chronic leg wounds, and wearable monitoring technology for managing such wounds. The platform combines hardware with a HIPAA-compliant mobile application and a cloud dashboard to track metrics such as walking, leg elevation, dressing saturation, and compression bandage pressure. By generating actionable insights, it supports adherence to treatment, optimizes the timing of clinical interventions, and facilitates integration into existing care routines without frequent new appointments or infrastructure. The company also maintains a network of consultants specializing in wound care reimbursement, FDA regulation, clinical research, patent law, and healthcare compliance to address regulatory and reimbursement needs.

Jane Diagnostics has developed an innovative healthcare technology aimed at improving the detection of human papillomavirus (HPV) and, consequently, cervical cancer. The company offers a low-cost, easy-to-use diagnostic test that allows minimally trained health workers to conduct screenings in remote areas, providing results in under one hour. This technology integrates sample processing and DNA amplification, making it possible to detect various HPV genotypes without the need for extensive laboratory infrastructure or long transportation times. By simplifying the testing process, Jane Diagnostics is positioned to revolutionize HPV screening, particularly in developing regions, thereby enhancing early detection and potentially reducing cervical cancer incidence.

General Biotechnologies identifies and develops undervalued discoveries in the life sciences. Their flagship program — Nivien Therapeutics — is a venture-backed oncology startup spun out of Harvard Medical School.